Clinical Trials Logo

Vaccination Reaction clinical trials

View clinical trials related to Vaccination Reaction.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05160766 Completed - COVID-19 Clinical Trials

Assessing Immune Response of Different COVID-19 Vaccines in Older Adults

EU-COVAT-1
Start date: November 8, 2021
Phase: Phase 2
Study type: Interventional

This is a randomised controlled, adaptive, multicentre Phase II protocol evaluating different booster strategies in individuals aged 75 years and older already vaccinated against SARS-CoV-2. Part B of this trial foresees testing of different vaccines as a 4th vaccination dose (second booster) for comparative assessment of their immunogenicity and safety against SARSCoV- 2 wild-type and variants in the elderly, a usually neglected population. Additional vaccines and extended follow-up visits can be added through amendments of this sub-protocol. As stated in the EU-COVAT master protocol, this trial, i.e., the EU-COVAT-1_AGED study, implements a specific safety monitoring strategy (see below). Cohorts and arms can be withdrawn or added as deemed necessary according to the criteria specified in this protocol

NCT ID: NCT05043168 Completed - Covid19 Clinical Trials

Kidney Histopathology After COVID-19 and SARS-CoV-2 Vaccination

Start date: September 18, 2021
Phase:
Study type: Observational

The study aims to summarize kidney histopathological findings in patients with coronavirus disease 2019 (COVID-19) and post-severe acute respiratory syndrome-coronavirus-type 2 (SARS-CoV-2) vaccination.

NCT ID: NCT04934215 Completed - Clinical trials for SARS CoV 2 Infection

Evaluation of Post-vaccination Anti-SARS-CoV-2 Serological Response in Health Care Workers With a History of COVID-19.

VACCICOVID
Start date: July 28, 2021
Phase:
Study type: Observational

Since the beginning of 2020, a major pandemic due to the new emerging coronavirus (SARS-CoV-2) has been spreading around the world. Today, the hope to contain this pandemic lies in the development and use of vaccines directed against this virus. Different strategies aim to maximize the early impact of vaccination in a context where few doses are available. In early January 2021, large-scale vaccination began in France, first for populations at risk of severe COVID-19, but also for healthcare workers over 50 years of age or with an underlying pathology, and then for all voluntary healthcare workers.